CD36作为急性髓系白血病预后标志物的系统评价
CD36 as a marker of acute myeloid leukemia prognosis: A systematic review.
作者信息
Amantéa Marina Chaves, da Silva Rafaela Pires, Soares Larissa Ranini, Pereira João Lorenzo de Medeiros, de Souza Ana Paula Duarte
机构信息
Escola de Ciências da Saúde e da Vida, Pontifícia Universidade Católica do Rio Grande do Sul (PUCRS), Porto Alegre, RS, Brazil.
Escola de Ciências da Saúde e da Vida, Pontifícia Universidade Católica do Rio Grande do Sul (PUCRS), Porto Alegre, RS, Brazil.
出版信息
Hematol Transfus Cell Ther. 2025 Jun 16;47(3):103861. doi: 10.1016/j.htct.2025.103861.
CD36 is a glycoprotein associated with resistance to chemotherapy and the recurrence of acute myeloid leukemia. This systematic review aims to evaluate the impact of CD36 on the prognosis of acute myeloid leukemia, a complex heterogeneous malignant hematopoietic disease. The Embase, Scopus, Web of Science, Cochrane Library and SciELO databases were searched until September 2023. Only studies that analyzed CD36 expression in humans were included. Of 905 articles identified from the databases, 600 were screened and nine were included. The Newcastle-Ottawa Scale was used to evaluate the methodological quality of the studies. According to this systematic review, CD36 is associated with different prognostic factors in acute myeloid leukemia, including remission and relapse of the disease, overall survival, and chemoresistance.
CD36是一种与化疗耐药及急性髓系白血病复发相关的糖蛋白。本系统评价旨在评估CD36对急性髓系白血病（一种复杂的异质性恶性血液病）预后的影响。检索了Embase、Scopus、Web of Science、Cochrane图书馆和SciELO数据库，直至2023年9月。仅纳入分析人类CD36表达的研究。从数据库中识别出的905篇文章中，筛选出600篇，纳入9篇。采用纽卡斯尔-渥太华量表评估研究的方法学质量。根据本系统评价，CD36与急性髓系白血病的不同预后因素相关，包括疾病的缓解和复发、总生存期及化疗耐药。
Zotero 插件